The standard of care for diabetic retinopathy and diabetic macular edema is insufficient.
Current treatments only delay disease progression in a portion of all patients. They also require maintaining a strict monthly / bi-monthly treatment schedule, resulting in low compliance
At Angios we aim to identify therapeutics that act on a broader patient population and lead to amore sustainable treatment response.
